Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Multiple Myeloma 2Lymphoma 2

Interventions

Dexamethasone 33Lenalidomide 14pomalidomide 12daratumumab 12Bortezomib 12venetoclax 7Cyclophosphamide 7isatuximab 6Therapeutics 6trametinib 4carfilzomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3fludarabine 3dabrafenib 3Vemurafenib 3Rituximab 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Drug Therapy 3Denosumab 3Ciprofloxacin 3Calcium Dobesilate 3ridaforolimus 2pembrolizumab 2molibresib 2liposomal amphotericin B 2fludarabine phosphate 2cobimetinib 2afuresertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × ridaforolimus × Plasma cell × Clear all
NCT00060632 2015-08-27

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
46 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00060645 2015-08-27

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
33 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡